Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
2021-06-18 16:59:06
Oslo, Norway, 18 June 2021
Reference is made to the stock exchange notice published 2 June 2021 regarding
allocation of restricted stock units to members of the board of directors of
Nordic Nanovector ASA ("Nordic Nanovector" or the "Company").
Primary insider notifications for the same already notified transactions
pursuant to the Market Abuse Regulation article 19 are attached hereto.
For further information, please contact:
Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.
Further information can be found at www.nordicnanovector.com.
This information is subject to a duty of disclosure pursuant to the Market Abuse
Regulation article 19 and 5-12 of the Securities Trading Act.